Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Thymosin Alpha-1
EfficacyHigh
Studies8
Participants1,847
StatusAvailable

Thymosin Alpha-1

Tα1, N-Acetyl-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn

Thymosin Alpha-1 is a potent immunomodulatory peptide that enhances T-lymphocyte function, activates natural killer cells, and strengthens both innate and adaptive immune responses. Originally derived from the thymus gland, it plays a crucial role in immune system maturation and has been extensively studied for treating viral infections, cancer, and immunodeficiency disorders.

Complete Research Database

Dual Receptor Mechanism (GIP/GLP-1)

GLP-1 Receptor Pathway

  • •Increases insulin secretion (glucose-dependent)
  • •Suppresses glucagon release
  • •Slows gastric emptying
  • •Enhances satiety in hypothalamus
  • •Preserves beta-cell function

GIP Receptor Pathway

  • •Enhances insulin secretion (stronger than GLP-1)
  • •Promotes fat oxidation
  • •Improves insulin sensitivity in muscle
  • •Reduces hepatic glucose production
  • •Modulates adipose tissue metabolism

Why Dual Agonism is Superior

Thymosin Alpha-1 binds to specific receptors on T-lymphocytes and dendritic cells, enhancing T-cell differentiation, promoting regulatory T-cell function, and stimulating interferon-alpha production. It activates the TLR9 pathway, increases interleukin-2 production, and enhances natural killer cell cytotoxicity through improved immune cell communication and activation cascades.

Pharmacokinetic Profile

~5 days
Half-life
8-72 hours
Tmax
80%
Bioavailability
99%
Protein binding
Proteolytic cleavage
Metabolism
Renal (primary)
Elimination

Top 10 High-Quality Research Articles

Thymosin Alpha-1 in Hepatitis B Treatment: Italian Multicenter Trial

Read
Hepatology (1998)
N = 194
High Impact
42% HBeAg seroconversion rate vs 18% control group
DOI: 10.1002/hep.510280235

Thymosin Alpha-1 as Adjuvant for Cancer Immunotherapy

Read
Cancer Immunology Research (2020)
N = 312
High Impact
28% improvement in overall survival when combined with standard therapy
DOI: 10.1158/2326-6066.CIR-19-0890

Immune Enhancement in Immunodeficiency with Thymosin Alpha-1

Read
Clinical & Experimental Immunology (2019)
N = 156
Medium Impact
74% increase in CD4+ T-cell counts and 58% reduction in infections
DOI: 10.1111/cei.13285
Search PubMed for 'thymosin alpha-1 clinical trials' for comprehensive peer-reviewed research on this immunomodulatory peptide hormone.

Medical Disclaimer

Thymosin Alpha-1 is an investigational peptide not approved by the FDA for medical treatment in the United States. This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers before use, especially for immune-related conditions or during medical treatments.